MedPath

安徽宏业药业有限公司

Ownership
-
Established
2009-09-01
Employees
-
Market Cap
-
Website
www.hongyeyaoye.com

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

90

NMPA:90

Drug Approvals

Compound Glycyrrhizin for Injection

Product Name
注射用复方甘草酸苷
Approval Number
国药准字H20080026
Approval Date
Dec 20, 2022
NMPA

Insulin Injection

Product Name
胰岛素注射液
Approval Number
国药准字H34021795
Approval Date
Oct 31, 2022
NMPA

Cefpirome Sulfate for Injection

Product Name
注射用硫酸头孢匹罗
Approval Number
国药准字H20066550
Approval Date
Aug 11, 2021
NMPA

Cefpirome Sulfate for Injection

Product Name
注射用硫酸头孢匹罗
Approval Number
国药准字H20066847
Approval Date
Aug 11, 2021
NMPA

Potassium Sodium Pehydroandroandrographolide Succinate for Injection

Product Name
注射用炎琥宁
Approval Number
国药准字H20064443
Approval Date
Jul 9, 2021
NMPA

Tiopronin for Injection

Product Name
注射用硫普罗宁
Approval Number
国药准字H20067698
Approval Date
Jul 9, 2021
NMPA

Potassium Sodium Pehydroandroandrographolide Succinate for Injection

Product Name
注射用炎琥宁
Approval Number
国药准字H20064442
Approval Date
Jul 9, 2021
NMPA

Cefonicid Sodium for Injection

Product Name
注射用头孢尼西钠
Approval Number
国药准字H20064636
Approval Date
Jul 2, 2021
NMPA

Cefonicid Sodium for Injection

Product Name
注射用头孢尼西钠
Approval Number
国药准字H20064635
Approval Date
Jul 2, 2021
NMPA

Thymopentin for Injection

Product Name
注射用胸腺五肽
Approval Number
国药准字H20065846
Approval Date
Jun 23, 2021
NMPA
  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 9
  • Next

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.